Skip to content
10-Q

Quarterly Report

Twist Bioscience Corporation TWST

0001581280-26-000040

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Apr 29, 2026 62.27M sh
Shares Diluted Q2 2026 · Mar 31, 2026 61.7M sh
Shares Diluted Q2 2026 · Mar 31, 2026 61.39M sh
Shares Diluted Q2 2026 · Mar 31, 2025 59.65M sh
Shares Diluted Q2 2026 · Mar 31, 2025 59.4M sh
Capex Q2 2026 · Mar 31, 2026 $17.86M
Capex Q2 2026 · Mar 31, 2025 $6.41M
Operating Cash Flow Q2 2026 · Mar 31, 2026 −$42.37M
Operating Cash Flow Q2 2026 · Mar 31, 2025 −$34.41M
Short Term Investments Q2 2026 · Mar 31, 2026 $49M
Short Term Investments Q2 2026 · Sep 30, 2025 $49.39M
Cash And Equivalents Q2 2026 · Mar 31, 2026 $122.67M
Cash And Equivalents Q2 2026 · Sep 30, 2025 $183.05M
Stockholders Equity Q2 2026 · Mar 31, 2026 $455.09M
Stockholders Equity Q2 2026 · Dec 31, 2025 $456.1M
Stockholders Equity Q2 2026 · Sep 30, 2025 $472.96M
Stockholders Equity Q2 2026 · Mar 31, 2025 $440.11M
Stockholders Equity Q2 2026 · Dec 31, 2024 $455.94M
Stockholders Equity Q2 2026 · Sep 30, 2024 $472.69M
Current Liabilities Q2 2026 · Mar 31, 2026 $119.98M
Current Liabilities Q2 2026 · Sep 30, 2025 $91.41M
Total Liabilities Q2 2026 · Mar 31, 2026 $221.12M
Total Liabilities Q2 2026 · Sep 30, 2025 $168.9M
Current Assets Q2 2026 · Mar 31, 2026 $323.44M
Current Assets Q2 2026 · Sep 30, 2025 $332.97M
Total Assets Q2 2026 · Mar 31, 2026 $676.21M
Total Assets Q2 2026 · Sep 30, 2025 $641.86M
Eps Diluted Q2 2026 · Mar 31, 2026 −$0.71
Eps Diluted Q2 2026 · Mar 31, 2026 −$1.21
Eps Diluted Q2 2026 · Mar 31, 2025 −$0.66
Eps Diluted Q2 2026 · Mar 31, 2025 −$1.19
Eps Basic Q2 2026 · Mar 31, 2026 −$0.71
Eps Basic Q2 2026 · Mar 31, 2026 −$1.21
Eps Basic Q2 2026 · Mar 31, 2025 −$0.66
Eps Basic Q2 2026 · Mar 31, 2025 −$1.19
Sga Expense Q2 2026 · Mar 31, 2026 $76.09M
Sga Expense Q2 2026 · Mar 31, 2026 $145.83M
Sga Expense Q2 2026 · Mar 31, 2025 $63.67M
Sga Expense Q2 2026 · Mar 31, 2025 $119.85M
Rd Expense Q2 2026 · Mar 31, 2026 $19.7M
Rd Expense Q2 2026 · Mar 31, 2026 $36.83M
Rd Expense Q2 2026 · Mar 31, 2025 $23.92M
Rd Expense Q2 2026 · Mar 31, 2025 $45.22M
Net Income Q2 2026 · Mar 31, 2026 −$44.02M
Net Income Q2 2026 · Mar 31, 2026 −$74.53M
Net Income Q2 2026 · Mar 31, 2025 −$39.33M
Net Income Q2 2026 · Mar 31, 2025 −$70.92M
Operating Income Q2 2026 · Mar 31, 2026 −$45.86M
Operating Income Q2 2026 · Mar 31, 2026 −$78.76M
Operating Income Q2 2026 · Mar 31, 2025 −$41.56M
Operating Income Q2 2026 · Mar 31, 2025 −$76.21M
Cost Of Revenue Q2 2026 · Mar 31, 2026 $53.59M
Cost Of Revenue Q2 2026 · Mar 31, 2026 $103.32M
Cost Of Revenue Q2 2026 · Mar 31, 2025 $46.77M
Cost Of Revenue Q2 2026 · Mar 31, 2025 $92.64M
Revenue Q2 2026 · Mar 31, 2026 $110.72M
Revenue Q2 2026 · Mar 31, 2026 $214.41M
Revenue Q2 2026 · Mar 31, 2025 $92.79M
Revenue Q2 2026 · Mar 31, 2025 $181.51M